Tarceva Receives Positive Opinion in Europe for Maintenance Treatment of Advanced Lung Cancer
Basel, Switzerland, March 19, 2010 (ots/PRNewswire) - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely ...